Skip to content
Medical Health Aged Care, Research Development

NeuRA launches world’s largest clinical trial for phantom limb pain

NeuRA (Neuroscience Research Australia) 2 mins read

Key points

  • NeuRA is now recruiting for TITAN, the world’s largest clinical trial to date into potential treatments phantom limb pain.  
  • Phantom limb pain is a condition that baffles scientists and affects up to 80% of people who have undergone limb amputation.
  • The trial will investigate the effectiveness of two drug-free treatments that aim to provide meaningful pain relief.

Exploring two new treatments

Researchers at NeuRA’s Centre for Pain Impact are carrying out world’s largest clinical trial for two potential treatments for phantom limb pain.

Phantom limb pain is a distressing and disabling condition that has baffled scientists and clinicians and affects up to 80% of people who have had a limb amputated or had a spinal cord injury.

NeuRA Senior Research Scientist and Director of the Centre for Pain Impact, Professor James McAuley, said the TITAN clinical trial would investigate the effectiveness of two promising treatments.

“There are currently no proven treatments that provide meaningful pain relief for people with phantom limb pain,” Prof McAuley said.

“This is a randomised clinical trial funded by the Commonwealth Government with the aim of reducing pain and improving function. Both treatments we are investigating are drug-free and aim to change how the brain processes pain signals coming from body. The first is a progressive rehabilitation program using techniques such as mirror therapy, while the second uses low frequency non-invasive neuromodulation.”

 

What is phantom limb pain?

Phantom limb pain is used to describe sensations in a body part that is no longer present. This may include feeling that the ‘phantom’ limb is in a specific position or shape, is moving, is warm or cold, is itching, tingling or an electric sensation.

Phantom limb pain most commonly occurs in people after a major limb amputation and often leads to social isolation and loss of independence,” Prof McAuley said.

“At its worst, the condition can cause unbearable symptoms, including intense burning, shooting, stabbing, crushing, and electric shock type sensations that can disrupt sleep and lead to depression and a loss of quality of life. In many cases, the symptoms last a lifetime with little, as most analgesic medicines have only small effects and are accompanied by significant side effects. We want to find treatments than can provide meaningful pain relief.”

Join the world's largest clinical trial

Researchers from NeuRA’s Centre for Pain Impact will run the randomised clinical trial. This is a large-scale, Australia-wide initiative that will be conducted online by physiotherapists, ensuring it is widely accessible.

“We’re now encouraging people who suffer from phantom-limb pain to join our trial,” Prof McAuley said.

To find out more or register interest, visit: https://neura.edu.au/project/titan-a-clinical-trial-for-phantom-limb-pain

ENDS

 

 


About us:

About NeuRA

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit research institute based in Sydney aiming to prevent, treat and cure brain and nervous system diseases, disorders and injuries through medical research.

 To learn more about NeuRA: www.neura.edu.au


Contact details:

Media Contacts
Katana Smith
Senior Media and PR Advisor
0452 140 477
katana.smith@neura.edu.au

Beatrix Kates 
Director of Communications
0421 320 769
b.kates@neura.edu.au

 

Media

More from this category

  • Medical Health Aged Care
  • 18/09/2024
  • 06:20
Royal Australian College of GPs

RACGP celebrates ACT Labor commitments on payroll tax and general practice

The Royal Australian College of GPs (RACGP) has praised election commitments from ACT Labor to support Canberrans’ access to GPs through a pragmatic approach to payroll tax and greater exposure to general practice for junior doctors, and support better access to ADHD diagnosis and management. ACT Chief Minister Andrew Barr and Minister for Health Rachel Stephen-Smith announced that following discussions with the RACGP’s NSW&ACT faculty, if re-elected ACT Labor will: exempt income earned by GPs for bulk-billed services from payroll tax liabilities from 1 July 2025, aligning the ACT’s approach with Victoria and South Australia co-design a $4 million professional…

  • Contains:
  • Medical Health Aged Care
  • 18/09/2024
  • 06:05
Royal Australian College of GPs

No substitute for a good GP: doctors urge politicians to invest in general practice for NSW

GPs are the best medicine for New South Wales’ struggling health system – that's the message from doctors visiting the NSW Parliament today to call for investment to improve the health of communities across the state. Today, GPs are meeting with politicians to advocate for the health of their patients and communities, in a visit organised by the Royal Australian College of GPs (RACGP). RACGP NSW Chair Dr Rebekah Hoffman said: “New South Wales needs GPs more than ever – and every politician should understand the importance of general practice care for their community. “Over seven million people in New…

  • Medical Health Aged Care
  • 17/09/2024
  • 22:56
Ripple Therapeutics

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.Ripple's patented technology platform is based on…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.